Literature DB >> 20655547

Elevated plasma levels of tissue inhibitors of metalloproteinase-1 and their overexpression in muscle in human and mouse muscular dystrophy.

Guilian Sun1, Kazuhiro Haginoya, Yoko Chiba, Mitsugu Uematsu, Naomi Hino-Fukuyo, Soichiro Tanaka, Akira Onuma, Kazuie Iinuma, Shigeru Tsuchiya.   

Abstract

To investigate the role of tissue inhibitors of metalloproteinases (TIMPs) in muscular dystrophy, we examined the expression of TIMP-1 using plasma and biopsied muscle from patients with various muscular dystrophies by ELISA, immunohistochemistry, and Western blot analysis. TIMP-1 immunolocalization was also studied in mouse models of muscular dystrophy. Plasma TIMP-1 was elevated and correlated with TGF-β1 in Duchenne muscular dystrophy (DMD) and congenital muscular dystrophy (CMD), but not in Becker muscular dystrophy. In dystrophic human muscles, TIMP-1 was immunopositive in the regenerating and non-regenerating muscle fibers, and interstitial cells that consist of activated fibroblasts and macrophages. TIMP-1 immunoreactivity was also closely associated with TGF-β1. Western blot analysis showed elevated TIMP-1 protein in muscles in DMD. The semiquantitative analysis of TIMP-1 staining intensity and tissue fibrosis showed that TIMP-1 immunoreactivity is closely associated with the extent of tissue fibrosis in human and mouse dystrophic muscles. In conclusion, the present study implied that the TGF-β1-TIMP-1 pathway is activated in dystrophic muscles and the overexpression of TIMP-1 may result in increased deposition of extracellular matrix leading to tissue fibrosis. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655547     DOI: 10.1016/j.jns.2010.06.031

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.

Authors:  D M Escolar; A Zimmerman; T Bertorini; P R Clemens; A M Connolly; L Mesa; K Gorni; A Kornberg; H Kolski; N Kuntz; Y Nevo; C Tesi-Rocha; K Nagaraju; S Rayavarapu; L P Hache; J E Mayhew; J Florence; F Hu; A Arrieta; E Henricson; R T Leshner; J K Mah
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

2.  Comparative transcriptome analysis of muscular dystrophy models Large(myd), Dmd(mdx)/Large(myd) and Dmd(mdx): what makes them different?

Authors:  Camila F Almeida; Poliana Cm Martins; Mariz Vainzof
Journal:  Eur J Hum Genet       Date:  2016-03-02       Impact factor: 4.246

Review 3.  Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles.

Authors:  Hala S Alameddine; Jennifer E Morgan
Journal:  J Neuromuscul Dis       Date:  2016-11-29

4.  Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy.

Authors:  Sandra Murphy; Paul Dowling; Margit Zweyer; Michael Henry; Paula Meleady; Rustam R Mundegar; Dieter Swandulla; Kay Ohlendieck
Journal:  Int J Mol Med       Date:  2017-04-18       Impact factor: 4.101

5.  Mechanotherapy Reprograms Aged Muscle Stromal Cells to Remodel the Extracellular Matrix during Recovery from Disuse.

Authors:  Zachary R Hettinger; Yuan Wen; Bailey D Peck; Kyoko Hamagata; Amy L Confides; Douglas W Van Pelt; Douglas A Harrison; Benjamin F Miller; Timothy A Butterfield; Esther E Dupont-Versteegden
Journal:  Function (Oxf)       Date:  2022-03-24

6.  Paraspinal Muscle Health is Related to Fibrogenic, Adipogenic, and Myogenic Gene Expression in Patients with Lumbar Spine Pathology.

Authors:  Brad Anderson; Angel Ordaz; Vinko Zlomislic; R Todd Allen; Steven R Garfin; Regula Schuepbach; Mazda Farshad; Simon Schenk; Samuel R Ward; Bahar Shahidi
Journal:  BMC Musculoskelet Disord       Date:  2022-06-24       Impact factor: 2.562

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.